Abstract
Expert consensus on HIV-1 protease inhibitors—much like the broader question of when and in whom to start therapy—seems to swing back and forth. In The Lancet today, Joseph Eron and colleagues1 present unexpected results from two multicentre non-inferiority trials (SWITCHMRK 1 and 2), which were identically designed to assess whether switching of the protease inhibitor component of a treatment regimen to an integrase inhibitor would reduce adverse effects (especially hyperlipidaemia) while maintaining viral-load suppression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
